Sangamo Therapeutics, Inc. Earnings Recaps
Q1 2026
May 16, 2026
Sangamo’s stock declined 4.3% following the quarter, reflecting investor concerns about the NASDAQ delisting and the continued uncertainty regarding capital availability, which clouds the company’s path to completing the BLA submission and advancing its pipeline.
Key takeaways
- The company transitioned to trading on the OTCQB Venture Market after NASDAQ delisting due to minimum bid requirement noncompliance, heightening market uncertainty.
- The rolling BLA submission for ST-920 in Fabry disease is ongoing, with the first 2 modules submitted; completion is contingent on securing additional funding.
- Six clinical sites activated for the Phase I/II STAND study of ST-503 in neuropathic pain, with preclinical safety data published.
- Progress continues on the ST-506 prion disease program, including ongoing GLP toxicology analysis and regulatory discussions with the UK MHRA.
- Sangamo emphasized strategic efforts to raise capital and explore partnerships, underscoring the critical importance of financing to sustain operations and development milestones.
Q3 2025
Nov 7, 2025
Sangamo Therapeutics reported significant advancements in its clinical pipeline for Fabry disease, highlighted by promising data from its STAAR study and a positive interaction with the FDA regarding its upcoming BLA submission.
Key takeaways
- Presented compelling clinical data from the STAAR study, showing durable benefits of ST-920, with a mean annualized eGFR slope of nearly 2 at 52 weeks across all patients.
- FDA meeting confirmed agreement to use eGFR slope as an endpoint for an accelerated approval pathway, with plans for a BLA submission anticipated in early 2026.
- Initiated the Phase I/II STAND study for chronic neuropathic pain, expanding Sangamo's reach into neurology.
- Emphasized the strong safety profile and durable efficacy of ST-920, including encouraging cardiac data from treated patients.
- Focused commitment to addressing unmet needs within the Fabry community, bolstered by patient engagement and feedback.